Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice
Targeting FOLR1 with an approved antibody-drug conjugate restored anti-tumor immunity and enhanced anti-PD-1 effectiveness in colorectal cancer, overcoming immune evasion in mouse models.